BrainStorm Issues 2019 Letter to Shareholders NEW YORK, Dec. 18, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapeutics for neurodegenerative diseases, today issued a Letter to...

BrainStorm Selected as Buzz of BIO 2020 Winner NEW YORK, Dec. 11, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in the development of innovative autologous cellular therapies for highly debilitating...

BrainStorm Cell Therapeutics Announces Publication of NurOwn® ALS Phase 2 Randomized Clinical Trial Data in Neurology A single transplantation of MSC-NTF cells (NurOwn®) in ALS clinical trial participants met the primary safety endpoint and demonstrated promising stabilization of ALS disease progression of up to...